



Repair Therapeutics to Participate in Two Upcoming Investor Conferences

November 6, 2023

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Nov. 6, 2023-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:

Stifel 2023 Healthcare Conference

Date: Tuesday, November 14, 2023

Time: 8:35 a.m. Eastern Time

Location: New York, NY

Piper Sandler 35th Annual Healthcare Conference

Date: Tuesday, November 28, 2023

Time: 10:30 a.m. Eastern Time

Location: New York, NY

A live webcast of the fireside chats can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Repair Therapeutics, Inc.

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on [X](#) (formerly Twitter) and [LinkedIn](#).

SNIPRx® is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231106081922/en/): <https://www.businesswire.com/news/home/20231106081922/en/>

Repair Contact:

Steve Forte

Executive Vice-President and Chief Financial Officer

Repair Therapeutics Inc.

investor@reparerx.com

Investors:

Matthew DeYoung

Argot Partners

repare@argotpartners.com

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Repair Therapeutics Inc.